Evaxion Seeks Shareholder Approval for Highly Dilutive Capital Raise Authorizations

summarizeSummary

Evaxion A/S has convened its Annual General Meeting to seek shareholder approval for significant authorizations, including the potential issuance of warrants and convertible loan notes that could lead to over 80% dilution of existing shares.

check_boxKey Events

• Annual General Meeting Convened

  Evaxion A/S announced its Annual General Meeting for April 16, 2026, to vote on several key proposals.

• Authorization for Warrants Proposed

  Shareholders will vote on increasing the authorization to issue warrants to employees and management, which could lead to a potential 11.4% dilution of current shares outstanding.

• Authorization for Convertible Notes Proposed

  A proposal seeks approval for a new authorization to obtain loans against the issuance of convertible loan notes up to DKK 73.5 million nominal value, which could result in a substantial 70.5% dilution if fully converted.

• New Board Member Proposed

  Jens Bitsch-Nørhave, a dynamic life science executive with over 25 years of leadership experience, is proposed for election as a new member of the board of directors.

auto_awesomeAnalysis

Evaxion A/S has convened its Annual General Meeting to seek shareholder approval for significant authorizations that, if fully utilized, would substantially dilute existing shareholders. The proposals include increasing the authorization to issue warrants to employees and management, which could lead to an 11.4% dilution, and a new authorization to issue convertible loan notes up to DKK 73.5 million nominal value, potentially resulting in a massive 70.5% dilution. Combined, these authorizations represent a potential increase of over 80% in the total number of outstanding shares. While these are authorizations and not immediate issuances, they signal a substantial future need for capital that will likely come at a significant cost to current equity holders. Additionally, the company proposes the election of Jens Bitsch-Nørhave, a seasoned life science executive, to the board, which is a positive governance change, but it is overshadowed by the scale of potential dilution.